N18
Conditions
Interventions
Group 1: Proteinuria: uACR > 300 mg/g creatinine AND eGFR > 45 ml/min 1,73m2
Group 2: CKD: eGFR = 30 ml/min 1,73m2 independent of proteinuria
Group 3: Control: eGFR > 60ml/min 1,73m2 AND uACR < 30 mg/
Sponsors
Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg
Eligibility
Sex/Gender
All
Age
18 Years to 89 Years
Inclusion criteria
Inclusion criteria: - Determination of eGFR from serum creatinine and urine ACR on the day of recruitment - Written informed consent
Exclusion criteria
Exclusion criteria: - Need for renal replacement therapy - Presence of a functional kidney transplant - Treatment with any immunosuppressive medication within the last 4 weeks - Treatment with rituximab, obinutuzumab, or cyclophosphamide within the last 12 months - Infections at the time of the study or within 2 weeks before the study - Child-Pugh stage C liver cirrhosis - Active malignancy with or without specific oncological therapy - Blood transfusion within 4 weeks before inclusion, severe anemia with current indication for blood transfusion - Presence of pregnancy - Lack of consent to participate in the study - Inability to understand study procedures and provide valid informed consent - Persons who are housed in an institution by court or official order - Simultaneous participation in an interventional study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of CD137 on CD4+ T-lymphocytes under halfmaximal stimulation by SEB in vitro | — |
Secondary
| Measure | Time frame |
|---|---|
| monocyte subpopulation distribution in blood, T-cell activation in vitro | — |
Countries
Germany
Contacts
Public ContactMatthias Girndt
Klinik für Innere Medizin II, Martin-Luther-Universität Halle-Wittenberg
Outcome results
None listed